Halozyme Therapeutics, Inc. has implemented a new drug development strategy and plans to decrease research relating to the discovery and preclinical development of new compounds. The company will focus resources on its advanced programs and partnership activities in 2011 and 2012, resulting in layoffs of approximately 25% of its workforce. Halozyme will continue development of its Phase II Ultrafast Insulin, Phase I PEGPH20, and preclinical HTI-501 programs. The company expects to incur a one...